Catalog# |
Product Description |
Product Type |
Size |
200-200-HAH |
Human Anti-Human
IgG (HAHA) ELISA kit, 96 tests |
Kit |
1 kit |
200-205-HAM |
Human Anti-Mouse
IgG (HAMA) ELISA kit, 96 tests |
Kit |
1 kit |
200-210-RAG |
Rituximab/Rituxan/Anti-CD20
(Active) ELISA Kit (Human/mouse/rat),96 tests |
Kit |
1 kit |
200-245-HAM |
Human
Anti-Rituximab/Rituxan (HADA/HAMA) IgG ELISA kit for human, 96 tests |
Kit |
1 kit |
200-300-ADG |
Humira/Adalimumab
(Human Anti-TNF-alpha) ELISA Kit for dog, 96 tests |
Kit |
1 kit |
200-310-ADG |
Humira/Adalumumab
(Human Anti-TNF-alpha) ELISA Kit for human, 96 tests |
Kit |
1 kit |
200-310-AHG |
Humira/Adalimumab
(Human Anti-TNF-alpha) ELISA Kit for human, 96 tests |
Kit |
1 kit |
200-320-ADG |
Human
Anti-Humira/Adalimumab (Human Anti-TNF-alpha) IgG ELISA Kit, 96 tests |
Kit |
1 kit |
200-320-AHG |
Human
Anti-Humira/Adalimumab (Human Anti-TNF-alpha) ELISA Kit for human, 96 tests |
Kit |
1 kit |
200-330-TNF |
Human TNF-alpha
ELISA Kit, 96 tests |
Kit |
1 kit |
200-410-XLG |
Xolair/Omalizumab
ELISA Kit for human, 96 tests |
Kit |
1 kit |
200-420-XLG |
Human
Anti-Xolair/Omalizumab Antibody ELISA Kit for human, 96 tests |
Kit |
1 kit |
200-430-XET |
Human IgE
(total) ELISA Kit for Xolair-treated samples, 96 tests |
Kit |
1 kit |
200-440-XEF |
Human IgE (Free;
Xolair unbound) ELISA Kit for Xolair-treated samples, 96 tests |
Kit |
1 kit |
200-510-HLG |
Herceptin/Trasuzumab
ELISA Kit for human, 96 tests |
Kit |
1 kit |
200-520-HAG |
Human
Anti-Herceptin/Trasuzumab Antibody (HAHA) Kit 96 tests |
Kit |
1 kit |
200-530-HER |
Her2/neu/Erbb2/CD340
protein ELISA kit, 96 tests |
Kit |
1 kit |
200-600-HRH |
Human Anti-Her2
Protein (ECD) IgG ELISA kit for Her2 vaccine, 96 tests, Quantitative |
Kit |
1 Kit |
200-610-HRM |
Human Anti-Her2
Protein (ECD) IgM ELISA kit for Her2 vaccine, 96 tests, Quantitative |
Kit |
1 Kit |
200-620-HRH |
Mouse Anti-Her2
Protein (ECD) ELISA kit for Her2 vaccine, 96 tests, Quantitative |
Kit |
1 Kit |
200-630-HRM |
Mouse Anti-Her2
Protein (ECD) IgM ELISA kit for Her2 vaccine, 96 tests, Quantitative |
Kit |
1 Kit |
200-640-HRH |
Human Anti-Her2
vaccine (E75-peptide) IgG ELISA kit, 96 tests, Quantitative |
Kit |
1 Kit |
200-650-HRM |
Human Anti-Her2
vaccine (E75-peptide) IgM ELISA kit, 96 tests, Quantitative |
Kit |
1 Kit |
200-660-HRH |
Mouse Anti-Her2
vaccine (E75-peptide) IgG ELISA kit, 96 tests, Quantitative |
Kit |
1 Kit |
200-670-HRM |
Mouse Anti-Her2
vaccine (AE37-peptide) IgM ELISA kit, 96 tests, Quantitative |
Kit |
1 Kit |
200-700-HRH |
Human Anti-Her2
vaccine (AE37-peptide) IgG ELISA kit, 96 tests, Quantitative |
Kit |
1 Kit |
200-710-HRM |
Human Anti-Her2
vaccine (AE37-peptide) IgM ELISA kit, 96 tests, Quantitative |
Kit |
1 Kit |
200-720-HRH |
Mouse Anti-Her2
vaccine (AE37-peptide) IgG ELISA kit, 96 tests, Quantitative |
Kit |
1 Kit |
200-730-HRM |
Mouse Anti-Her2
vaccine (AE37-peptide) IgM ELISA kit, 96 tests, Quantitative |
Kit |
1 Kit |
200-800-AVG |
Avastin/Bevacizumab (Anti-VEGF) ELISA Kit for human, 96 tests |
Kit |
1 Kit |
200-810-ADG |
Human Anti-Avastin/Bevacizumab IgG (anti-drug IgG) ELISA Kit for human, 96 tests |
Kit |
1 Kit |
200-870-ID24 |
Avastin/Bevacizumab identification/Counterfeit detection ELISA Kit, 24 tests |
Kit |
1 Kit |
CD20-141-R |
Recombinant
Human CD20/MS4A1-mFC fusion Protein (141-184, 44-aa, ECD, rituximab-binding peptide) |
Recombinant
protein |
20 ug |
CD20-142-P |
Human CD20/MS4A1
linear peptide (142-184, 43-aa, extracellular domain) rituximab-binding peptide, >95% pure |
peptide |
100 ug |
CD20-145-R |
Recombinant (HEK
cells) purified human CD20/MS4A1 (213-297 aa) his tag Protein |
Recombinant
protein |
20 ug |
CD20-146-R |
Recombinant (HEK
cells) human CD20/MS4A1 (141-184 aa) hFc- fusion Protein |
Recombinant
protein |
10 ug |
CD20-147-R |
Recombinant (HEK
cells) purified Ferrret CD20/MS4A1 (213-297 aa) his tag Protein |
Recombinant
protein |
10 ug |
CD20-165-P |
human CD20/MS4A1
linear peptide (165-184, 20-aa, extracellular domain) broad reactivity with CD20-specific antibodies |
peptide |
100 ug |
CD20-1731-P |
Human CD20/MS4A1
peptide (Acetyl-cPYaNPSLc, 9-aa, Cyclic Cys1-Cys9);
contains ANPS motif and reactivity with Rituximab |
cyclic peptide |
100 ug |
CD20-1732-P |
Human CD20/MS4A1
cylcic peptide (Acetyl-cWAANPSMAc, 11 aa, Cys1-Cys11);
contains the ANPS motif and avidity for rituximab |
cyclic peptide |
100 ug |
CD20-1733-P |
Human CD20/MS4A1
cyclic peptide (Acetyl-cPYsNPSLc; 9aa, Cys1-Cys9; contains
NPS motif and react with rituximab |
cyclic peptide |
100 ug |
CD20-182-P |
Human CD20/MS4A1
linear peptide (CWWEWTIGC, 9-aa) contains motif WEWTI
of human CD-20 for rtiuximab |
peptide |
100 ug |
CD20-21-M |
Monoclonal
Anti-Human CD20/MS4A1 peptide (EC-domain, rituximab binding) ascites |
Antibodies |
100 ul |
CD20-22-A |
Anti-Human
CD20/MS4A1 peptide (EC-domain, rituximab binding domain) IgG, aff pure |
Antibodies |
100 ul |
CD20-22-P |
Anti-Human
CD20/MS4A1 control/blocking peptide (EC-domain, rituximab binding domain) |
Antibodies |
100 ug |
CD20-23-M |
Humanized
(chimeric) Anti-Human CD20/MS4A1 IgG (rituximab biosimilar), pure |
Antibodies |
100 ul |
CD20-RP1L-P |
CD20/MS4A1
linear peptide (WPRWLEN, 7-aa) contains motif WPXWLE, 6-aa; Rp1L-1) and reacts with rituximab |
peptide |
100 ug |
CD20-RP5L-P |
CD20/MS4A1
linear peptide (QDKLTQWPKWLEg, 13-aa) contains WPXWLE motif and reacts with rituximab |
peptide |
100 ug |
HER2-369-A |
Anti-HER2
peptide IgG (cyclic 367-37; E75 vaccine candidate) Aff pure |
Antibodies |
100 ul |
HER2-597-A |
Anti-HER2
peptide IgG (cyclic 597-626 vaccine candidate) Aff pure |
Antibodies |
100 u |
HER21-R-10 |
Recombinant
(HEK) human Her2/Erbb2/Neu (1-652)-hIgG-Fc fusion protein |
|
10 ug |
HER22-R-5 |
Recombinant
(sf9) human Her2/Erbb2/Neu (676-1255)-GST fusion protein |
|
5 ug |
HER23-R-10 |
Recombinant
(HEK) human Her2/Erbb2/Neu (1-652)-his tag fusion protein |
|
10 ug |
HER24-R-10 |
Recombinant
(HEK) mouse Her2/Erbb2/Neu (1-653)-his tag fusion protein |
|
10 ug |
HER25-R-10 |
HER2/ErB2
recombinant protein (1-652, extracellular domain), Human (E. coli) |
|
10 ug |
HER26-R-10 |
Recombinant
(HEK) rat Her2/Erbb2/Neu (4-656)-his tag fusion protein |
|
10 ug |
HER27-R-10 |
Recombinant
(HEK) rat Her2/Erbb2/Neu (4-656)-his tag fusion protein |
|
10 ug |
HER28-R-10 |
Recombinant
(HEK) rat Her2/Erbb2/Neu (4-656)-hIgG1-Fc fusion protein |
|
10 ug |
HER29-R-10 |
Recombinant
(HEK) monkey/rhesus Her2/Erbb2/Neu (1-652)-his tag fusion protein |
|
10 ug |
HER30-R-10 |
Recombinant
(HEK) monkey/rhesus Her2/Erbb2/Neu (1-652)-hIgG1-Fc fusion protein |
|
10 ug |
HER31-M |
Rabbit mono
anti-human Her2/Erbb2/Neu (1-652) protein IgG |
|
100 ul |
HER32-A |
Anti-human
Her2/Erbb2/Neu (1-652) protein IgG |
|
100 ul |
HER33-M |
Mouse mono
anti-monkey/rhesus Her2/Erbb2/Neu (1-652) protein IgG |
|
100 ul |
HER34-A |
Anti-monkey/rhesus
Her2/Erbb2/Neu (1-652) protein IgG |
|
100 ul |
RP1L-P |
CD20/MS4A1
linear peptide (WPRWLEN, 7-aa) contains motif WPXWLE, 6-aa; Rp1L-1) and reacts with rituximab |
peptide |
100 ug |
RP5L-P |
CD20/MS4A1
linear peptide (QDKLTQWPKWLEg, 13-aa) contains WPXWLE motif and reacts with rituximab |
peptide |
100 ug |
SM-101000-5 |
EGFR/HER2 kinase
inhibitor (>99%, M.wt 485.94) (Afatinib/BIBW-2992 |
Chemical |
5 mg |
SM-101000-50 |
EGFR/HER2 kinase
inhibitor (>99%, M.wt 485.94) (Afatinib/BIBW-2992 |
Chemical |
50 mg |
SM-101010-5 |
Inhibitor of
EGFR/HER family (Her1, Her2, Her3 or Pan Her-inhibitor) (BMS-59926/AC480, Mol wt 567.01, >99%) |
Chemical |
5 mg |
SM-101010-50 |
Inhibitor of
EGFR/HER family (Her1, Her2, Her3 or Pan Her-inhibitor) (BMS-59926/AC480, Mol wt 567.01, >99%) |
Chemical |
50 mg |
SM-101020-10 |
Inhibitor of
EGFR/HDAC/Her2 (CUDC-101; 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide, Mol wt
434.49, >99%) |
Chemical |
10 mg |
SM-101020-50 |
Inhibitor of
EGFR/HDAC/Her2 (CUDC-101; 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide, Mol wt
434.49, >99%) |
Chemical |
50 mg |
SM-101030-100 |
Lapatinib,
Inhibitor of Her2/EGFR (IC50=10 nM; mol wt 581; >98%) |
Chemical |
100 mg |
SM-101030-25 |
Lapatinib,
Inhibitor of Her2/EGFR (IC50=10 nM; mol wt 581; >98%) |
Chemical |
25 mg |
SM-101040-25 |
Cell permeable
Inhibitor of EGFR/ERB family/Her2 (Neratinib/HKI-272, mol wt 557.04; >98%) |
Chemical |
25 mg |
SM-101040-5 |
Cell permeable
Inhibitor of EGFR/ERB family/Her2 (Neratinib/HKI-272, mol wt 557.04; >98%) |
Chemical |
5 mg |
SM-101050-10 |
Cell permeable
Inhibitor of EGFR2/FGFR/PDGFr/JAK1/Her2 ((E)-4-((4-)1H-1,2,3-Triazol-1-yl)butyl)phenoxy)methyl)-2-(4-trifluoromethyl)oxazole,
mol wt 468; >98%) |
Chemical |
10 mg |
SM-101050-100 |
Cell permeable
Inhibitor of EGFR2/FGFR/PDGFr/JAK1/Her2 ((E)-4-((4-)1H-1,2,3-Triazol-1-yl)butyl)phenoxy)methyl)-2-(4-trifluoromethyl)oxazole,
mol wt 468; >98%) |
Chemical |
100 mg |
SM-101060-100 |
Lapatinib
Ditosylate (GW572016, GW2016, Tykerb, Tyverb), Autophos. Inhibitor of Her2/Erb2 (mol wt 925; >98%) |
Chemical |
100 mg |
SM-101060-25 |
Lapatinib
Ditosylate (GW572016, GW2016, Tykerb, Tyverb), Autophos. Inhibitor of Her2/Erb2 (mol wt 925; >98%) |
Chemical |
25 mg |
SM-101070-10 |
Canertinib
(CI-1033), kinase Inhibitor of Her2/Erb2/EGFR (mol wt 485; >98%) |
Chemical |
10 mg |
SM-101070-50 |
Canertinib
(CI-1033), kinase Inhibitor of Her2/Erb2/EGFR (mol wt 485; >98%) |
Chemical |
50 mg |
SM-101080-25 |
CP-724,714,
Potent and selective Inhibitor of Her2/Erb2 (mol wt 469; >98%) |
Chemical |
25 mg |
SM-101080-5 |
CP-724,714,
Potent and selective Inhibitor of Her2/Erb2 (mol wt 469; >98%) |
Chemical |
5 mg |
SM-101090-25 |
AZD8931,
reversible and competitive Inhibitor of Her2/Erbb2/ErbB3 (mol wt 473; >98%) |
Chemical |
5 mg |
SM-101090-5 |
AZD8931,
reversible and competitive Inhibitor of Her2/Erbb2/ErbB3 (mol wt 473; >98%) |
Chemical |
5 mg |
SM-101100-25 |
AEE788
(NVP-AEE788), dual Inhibitor of Her2/Erbb2/EGFR (mol wt 440; >98%) |
Chemical |
25 mg |
SM-101100-5 |
AEE788
(NVP-AEE788), dual Inhibitor of Her2/Erbb2/EGFR (mol wt 440; >98%) |
Chemical |
5 mg |
SM-101110-10 |
Mubritinib
(TAK-165), potent Inhibitor of Her2/Erbb2 (IC50=6 nm; mol wt 468; >98%) |
Chemical |
10 mg |
SM-101110-50 |
Mubritinib
(TAK-165), potent Inhibitor of Her2/Erbb2 (IC50=6 nm; mol wt 468; >98%) |
Chemical |
50 mg |
SM-101120-25 |
Arry-380, Oral,
potent Inhibitor of Her2/Erbb2 Tyr kinase (IC50=8 nM; mol wt 869; >98%) |
Chemical |
25 mg |
SM-101120-5 |
Arry-380, Oral,
potent Inhibitor of Her2/Erbb2 Tyr kinase (IC50=8 nM; mol wt 869; >98%) |
Chemical |
5 mg |
SM-101130-25 |
Tak-285, dual
Inhibitor of Her2/EGFR Tyr kinase (IC50=17 nM; mol wt 547; >98%) |
Chemical |
25 mg |
SM-101130-5 |
Tak-285, dual
Inhibitor of Her2/EGFR Tyr kinase (IC50=17 nM; mol wt 547; >98%) |
Chemical |
5 mg |